A team of Gleiss Lutz lawyers has advised the Swedish medtech company AddLife on the acquisition of Vision Ophthalmology Group GmbH, a leading provider of ophthalmic products and services. The initial purchase price, which can still increase by up to EUR 18 million, is EUR 165 million, of which 50 percent is being paid in cash and 50 percent via AddLife shares.
The medtech company AddLife, listed on Nasdaq Stockholm, offers products, services and advice in the field of medical technology throughout Europe. AddLife has about 1,100 employees in some 50 operating subsidiaries. The AddLife Group currently has net sales of around SEK 5 billion. With the acquisition of the Vision Ophthalmology Group, AddLife is expanding its product portfolio to include a new, strategically important therapeutic area in the growth market of ophthalmology.
Vision Ophthalmology Group GmbH is a leading provider of eye surgery products and services and has subsidiaries in Switzerland, Germany, the UK and Poland. The Group has approximately 190 employees and generated turnover of around EUR 70 million in 2020.
The following Gleiss Lutz team advised AddLife on the transaction: Dr. Ralf Morshäuser (partner, Munich), Jan Philipp Mohr (counsel, both lead), Dr. Patrick Mossler (partner, both Hamburg), Melina Grauschopf (Munich), Dr. Hendrik Quast (Hamburg, all M&A), Dr. Thomas Kulzer (counsel, Finance, Frankfurt), Dr. Alexander Molle (partner), Dr. Matthias Schilde (both IP/IT), Dr. Enno Burk (counsel), Dr. Christina Fröb (both Healthcare, all Berlin), Dr. Doris-Maria Schuster (partner), Alexandra-Helene Schwager (both Employment, Hamburg), Dr. Jonas Rybarz (counsel, Real Estate, Berlin), Dr. Petra Linsmeier (partner), Dr. Iris Benedikt-Buckenleib (counsel, both Competition/Antitrust, Munich).
Gleiss Lutz advised on the transaction together with the Swedish law firm Delphi, which is acting as lead counsel for AddLife.
Forward
